This clinical trial is focused on studying a condition known as chronic kidney disease, which affects the kidneys’ ability to filter waste from the blood. The trial will evaluate a new treatment called BAY 3283142, which is taken as a coated tablet. The purpose of the study is to learn how well this new drug works and how safe it is in reducing the amount of a protein called albumin in the urine of people with chronic kidney disease. Albumin in the urine is a sign that the kidneys are not working as well as they should.

Participants in the study will be randomly assigned to receive either the new drug BAY 3283142 or a placebo, in addition to their standard care. The study will last for 16 weeks, during which time the participants will take the medication orally. The researchers will monitor changes in the urine albumin-creatinine ratio, which is a measure used to assess kidney function. This will help determine the most effective dose of the new drug for future studies.

Throughout the study, participants will have regular check-ups to monitor their kidney function and overall health. The study aims to find the best dose of BAY 3283142 to help reduce albumin in the urine, which could potentially improve kidney health in people with chronic kidney disease. The results of this study will help guide further research and development of this treatment.